AVTX - NOTRELOAD AI

AVTX/ 05/05/2026 · 4:22 PM

Avalo Therapeutics Reports Strong Phase 2 Results for Abdakibart in Hidradenitis Suppurativa – Ready to Advance to Phase 3

Avalo’s abdakibart showed strong results in reducing HS symptoms in a Phase 2 trial, with a favorable safety profile and better outcomes than placebo.

PALI/ 04/09/2026 · 9:12 AM

Wolfe Research Initiates Coverage on Palisade Bio and Avalo Therapeutics with Strong Buy Calls

Wolfe Research: PALI “Outperform” ($7) eyes 2027 ulcerative colitis trial; AVTX “Outperform” ($48) waits May LOTUS Phase 2 readout.

AVTX/ 02/02/2026 · 7:53 AM

Guggenheim Gives Avalo Therapeutics a Buy Rating on AVTX-009

Guggenheim starts coverage of Avalo Therapeutics with a Buy rating, highlighting AVTX-009 as a promising IL-1beta treatment for Hidradenitis suppurativa (HS) and $2.1B peak sales potential.

#AVTX↓

Avalo Therapeutics Reports Strong Phase 2 Results for Abdakibart in Hidradenitis Suppurativa – Ready to Advance to Phase 3

Wolfe Research Initiates Coverage on Palisade Bio and Avalo Therapeutics with Strong Buy Calls

Guggenheim Gives Avalo Therapeutics a Buy Rating on AVTX-009